| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Champions Oncology (NASDAQ:CSBR) reported its Q3 earnings results on Tuesday, March 12, 2024 at 04:00 PM.
Here's what investors need to know about the announcement.
Champions Oncology missed estimated earnings by -7.000000000000001%, reporting an EPS of $-0.16 versus an estimate of $-0.15.
Revenue was down $754 thousand from the same period last year.
Last quarter the company beat on EPS by $0.02 which was followed by a 5.0% increase in the share price the next day.
Here's a look at Champions Oncology's past performance:
| Quarter | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| EPS Estimate | -0.17 | -0.10 | -0.12 | -0.03 |
| EPS Actual | -0.15 | -0.16 | -0.17 | -0.16 |
| Revenue Estimate | 12.84M | 13.06M | 12.86M | 13.13M |
| Revenue Actual | 11.57M | 12.56M | 13.07M | 12.77M |
To track all earnings releases for Champions Oncology visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: CSBR
